Logos Capital is a fundamental biotechnology-focused investment partnership that combines scientific and financial expertise with in-house clinical trial analytics to identify transformative therapies in healthcare. Based in San Francisco, Logos combines expertise across medical, scientific, and statistical disciplines to expand the depth of diligence in identifying compelling investment themes and opportunities.
Build a world-class biotechnology investment partnership, focused on generating superior long-term returns for our investors and financing innovation that will meaningfully advance the standard of care for patients
Success in drug development is contingent on more than just scientific research. Our process focuses on event tracking, clinical trial underwriting, risk management, and a culture rooted in technical diligence and continuous improvement. We seek to holistically assess an asset from its preclinical data through commercialization potential to determine intrinsic value.
We rigorously track and diligence all private and public companies in our sector, looking for best in class or first in class companies with attractive valuations.
New technologies and therapeutic approaches are leading to functional cures, expanding patient access, extending life expectancy and redefining the meaning of ‘value.’ We continually screen for opportunities that are clear advances to the current treatment paradigm and standard of care.
Our mandate is to deliver best-in-class returns to our investors. To do so, we thoroughly underwrite each investment, incorporating multiple layers of risk management to ensure our rationale, our “logos”, is perpetually aligned with those supporting us.
Logos Analytics is our in-house data science platform developed to help predict clinical trial outcomes.
Biotechnology is a data driven sector. Clinical trial outcomes dictate value creation or destruction, particularly for small and mid-sized companies. The role of data science at Logos is to simulate clinical data for a given trial and apply statistical tests to replicate what the company and FDA will do to determine if the trial was statistically significant and clinically meaningful (or not). There is no formulaic or algorithmic approach to definitively state that a trial will succeed or fail. Each investment presents its own unique project, data and frameworks to consider.
The inputs we use are varied based on available data. The analyses are dependent on the trial design as well as our assumptions and questions. However, the output is effectively the same – a refined probability of success that allows Logos to better understand the risk and the likelihood of reward. Logos Analytics tracks clinical data, builds comprehensive event calendar maps, and sources inputs from a wide variety of academic literature and drug development programs. Although we primarily use Logos Analytics to help determine probability of success or failure in clinical trials, we sometimes share our analysis with management teams.